ZA202106815B - Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof - Google Patents

Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof

Info

Publication number
ZA202106815B
ZA202106815B ZA2021/06815A ZA202106815A ZA202106815B ZA 202106815 B ZA202106815 B ZA 202106815B ZA 2021/06815 A ZA2021/06815 A ZA 2021/06815A ZA 202106815 A ZA202106815 A ZA 202106815A ZA 202106815 B ZA202106815 B ZA 202106815B
Authority
ZA
South Africa
Prior art keywords
diazabicyclo
octanylmethanone
pyrimidinyl
crystalline
compound
Prior art date
Application number
ZA2021/06815A
Other languages
English (en)
Inventor
Xiaojing Yang
Amanda Patrice Surajhie Samuel
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA202106815B publication Critical patent/ZA202106815B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
ZA2021/06815A 2019-02-15 2021-09-14 Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof ZA202106815B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962806180P 2019-02-15 2019-02-15
PCT/IB2020/051128 WO2020165788A1 (en) 2019-02-15 2020-02-12 Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof

Publications (1)

Publication Number Publication Date
ZA202106815B true ZA202106815B (en) 2026-03-25

Family

ID=69726639

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2021/06815A ZA202106815B (en) 2019-02-15 2021-09-14 Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof

Country Status (14)

Country Link
US (2) US12312358B2 (https=)
EP (1) EP3924355B1 (https=)
JP (1) JP7561497B2 (https=)
KR (2) KR20210114470A (https=)
CN (1) CN113646310A (https=)
AR (1) AR118099A1 (https=)
AU (1) AU2020222083B2 (https=)
BR (1) BR112021015951A2 (https=)
CA (1) CA3130034C (https=)
MX (1) MX2021009761A (https=)
SG (1) SG11202108863WA (https=)
TW (1) TWI820301B (https=)
WO (1) WO2020165788A1 (https=)
ZA (1) ZA202106815B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12312358B2 (en) * 2019-02-15 2025-05-27 Pfizer Inc. Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof
WO2021249367A1 (zh) * 2020-06-09 2021-12-16 苏州晶云药物科技股份有限公司 二氮杂双环类化合物的对甲苯磺酸盐新晶型及其制备方法
CN114835717A (zh) * 2021-02-01 2022-08-02 杭州领业医药科技有限公司 Brepocitinib甲苯磺酸盐的晶型及其制备方法和用途
CN113461687B (zh) * 2021-08-10 2022-04-19 四川大学华西医院 2,8-氮杂-[4,5]十螺环酮衍生物及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5023556A (en) 1990-02-02 1991-06-11 Conax Florida Corporation Sensor circuit response to different fluid conductivities and having time delay feature
GEP201606600B (en) 2013-02-22 2017-01-10 Pfizer Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
NO2721710T3 (https=) 2014-08-21 2018-03-31
SMT202400306T1 (it) * 2018-03-30 2024-09-16 Incyte Corp Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
US12312358B2 (en) * 2019-02-15 2025-05-27 Pfizer Inc. Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof

Also Published As

Publication number Publication date
KR102820235B1 (ko) 2025-06-16
TW202045511A (zh) 2020-12-16
JP2020138960A (ja) 2020-09-03
JP7561497B2 (ja) 2024-10-04
EP3924355A1 (en) 2021-12-22
MX2021009761A (es) 2021-12-15
CN113646310A (zh) 2021-11-12
AR118099A1 (es) 2021-09-15
AU2020222083A1 (en) 2021-09-02
BR112021015951A2 (pt) 2021-10-05
AU2020222083B2 (en) 2022-11-17
US20220144846A1 (en) 2022-05-12
WO2020165788A1 (en) 2020-08-20
EP3924355C0 (en) 2025-12-31
SG11202108863WA (en) 2021-09-29
KR20240116855A (ko) 2024-07-30
CA3130034A1 (en) 2020-08-20
EP3924355B1 (en) 2025-12-31
TWI820301B (zh) 2023-11-01
US20250282789A1 (en) 2025-09-11
KR20210114470A (ko) 2021-09-23
CA3130034C (en) 2023-12-19
US12312358B2 (en) 2025-05-27

Similar Documents

Publication Publication Date Title
ZA202106815B (en) Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof
ZA202007671B (en) Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and biguanide hypoglycemic drug as well as preparation method and use thereof
ZA202206923B (en) New methylquinazolinone derivatives
GEP201606555B (en) Compounds and compositions for modulating egfr activity
EP4467549A3 (en) Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
DE602004021472D1 (en) Pyrimiidinverbindungen
TW200801003A (en) Novel compounds
PH12020551891A1 (en) New quinoline derivatives
WO2020113213A3 (en) Cyclic pantetheine derivatives and uses thereof
AU2003228770A8 (en) Substituted pyrazolopyrimidines
JOP20220006A1 (ar) مشتقات 3، 6-داي أمينو-بيريدازين-3-يل، تركيبات صيدلية تحتوي عليها واستخدامها في صورة عوامل مساعدة على تلاشي الخلايا
MY200061A (en) Irak inhibitor and preparation method therefor and use thereof
WO2020127819A3 (en) Pharmaceutical composition comprising apixaban
GEP20257772B (en) Pyrrole compounds
CR20210181A (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
PH12020551342A1 (en) Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof
WO2020235974A3 (ko) 단일염기 치환 단백질 및 이를 포함하는 조성물
EP4643954A3 (en) Novel heterocyclic amine derivative and pharmaceutical composition comprising same
MY198008A (en) Crystal of benzofuran derivative free base and preparation method
EP4295916A3 (en) Salts of 4-amino-n-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and crystalline forms thereof
TW200639156A (en) New compounds
GEP20084306B (en) Antibacterial indolone oxazolidinones, intermediates for their preparation and pharmaceutical compositions containing them
JOP20200327A1 (ar) مركبات سيانوتريازول واستخداماتها
HUE072069T2 (hu) 2-((1R,4R)-4-((3-(3-(trifluormetil)fenil)imidazo[1,2- b]piridazin-6-il)amino)ciklohexil)propán-2-ol sósavas sójának kristályos formája
WO2004087652A3 (en) Imidazotriazine compounds